Skip to content

US · NVAX · BIOTECHNOLOGY

Novavax, Inc. (NVAX) intrinsic value and stock valuation

$7.47as of 2026-11-21 · Mkt cap 1.27B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Novavax, Inc. DCF and intrinsic value

InvestorsCraft values NVAX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NVAX’s statements →

Novavax, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Gaithersburg, MD 20878 novavax.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.12B+118.8% 5y CAGRd
20112025
Net income
$440.3M
20112025
Free cash flow
-$-250.19M
20112025
Total equity
-$-127.75M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.12B$682.2M$556.4M$1.6B$197.6M
Operating income$563.3M-$-248.93M-$-566.51M-$-644.74M-$-1.69B
Net income$440.3M-$-187.5M-$-545.06M-$-657.94M-$-1.74B
EPSd$2.54M-$-1.23M-$-5.41M-$-8.42M-$-23.44M
Operating cash flow-$-244.63M-$-87.26M-$-713.97M-$-415.94M$323M
Capital expenditure-$-5.56M-$-13.06M-$-58.81M-$-92.98M-$-57.49M
Free cash flow-$-250.19M-$-100.32M-$-772.77M-$-508.92M$265.5M
Total assets$1.18B$1.56B$1.8B$2.26B$2.58B
Total debt$248.8M$230.4M$229.1M$549.8M$454M
Net debt$8.18M-$-299.81M-$-339.42M-$-787.1M-$-1.06B
Total equity-$-127.75M-$-623.84M-$-716.93M-$-634.08M-$-351.67M
Cash and short-term investments$735.1M$923.1M$568.5M$1.34B$1.52B
Income statement
20252024202320222021
Revenue$1.12B$682.2M$556.4M$1.6B$197.6M
Cost of revenue$71.1M$202.7M$343.8M$902.6M$0.00
Gross profit$1.05B$479.4M$212.6M$696.3M$197.6M
Research and development expenses$336.8M$391.2M$737.5M$1.24B$2.53B
Selling, general and administrative expenses$150.4M$337.2M$469M$488.7M$298.4M
Other expenses$1.9M$0.00-$-427.32M-$-382.92M-$-948.71M
Operating expenses$489.1M$728.4M$779.1M$1.34B$1.88B
Cost and expenses$560.2M$931.1M$1.12B$2.24B$1.88B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$22.6M$20.1M$14.4M$19.9M$21.1M
Depreciation and amortization$27.6M$48.5M$41.2M$29.1M$12.7M
Ebitda$492.3M-$-108.04M-$-487.39M-$-604.71M-$-1.68B
Operating income$563.3M-$-248.93M-$-566.51M-$-644.74M-$-1.69B
Total other income/expenses, net-$-121.1M$72.3M$23.5M-$-8.91M-$-27.96M
Income before tax$442.2M-$-176.62M-$-543.03M-$-653.65M-$-1.71B
Income tax expense$1.86M$10.9M$2.03M$4.29M$29.2M
Net income$440.3M-$-187.5M-$-545.06M-$-657.94M-$-1.74B
Weighted average shares outstanding$162M$152.2M$100.8M$78.2M$74.4M
Weighted average diluted shares outstanding$173.1M$152.2M$100.8M$78.2M$74.4M
Balance sheet
20252024202320222021
Cash and short-term investments$735.1M$923.1M$568.5M$1.34B$1.52B
Net receivables$106.5M$108.3M$297.2M$82.4M$455M
Inventory$11.5M$8.75M$41.7M$36.7M$8.87M
Total current assets$978.3M$1.13B$1.14B$1.7B$2.16B
Property, plant and equipment, net$67.7M$300M$491M$400.5M$228.7M
Goodwill and intangible assets$113.5M$107.5M$127.5M$126.3M$136.3M
Long-term investments$0.00$0.00$0.00$1.66M$1.65M
Total non-current assets$198.2M$431.5M$653.6M$555.3M$421.6M
Total assets$1.18B$1.56B$1.8B$2.26B$2.58B
Accounts payable$24.6M$41.6M$132.6M$216.5M$127.1M
Short-term debt$2.51M$7.01M$5.14M$352.1M$130.5M
Deferred revenue$140.1M$675.1M$241.3M$370.1M$1.42B
Total current liabilities$460M$1.15B$1.64B$2.46B$2.39B
Long-term debt$246.3M$223.4M$223.9M$197.7M$323.5M
Deferred revenue, non-current$358.9M$446.8M$622.2M$179.4M$172.5M
Total non-current liabilities$844.3M$1.03B$879.3M$432.8M$538.1M
Capital lease obligations$4.6M$60.7M$61.1M$58.4M$130.5M
Total liabilities$1.3B$2.18B$2.51B$2.89B$2.93B
Common stock$1.65M$1.62M$1.41M$870K$760K
Retained earnings-$-4.57B-$-5.01B-$-4.82B-$-4.28B-$-3.62B
Accumulated other comprehensive income (loss)$2.01M-$-22.56M$2.72M-$-6.38M-$-1.35M
Total equity-$-127.75M-$-623.84M-$-716.93M-$-634.08M-$-351.67M
Total investments$494.5M$392.9M$0.00$1.66M$1.65M
Total debt$248.8M$230.4M$229.1M$549.8M$454M
Net debt$8.18M-$-299.81M-$-339.42M-$-787.1M-$-1.06B
Cash flow statement
20252024202320222021
Net income$440.3M-$-187.5M-$-545.06M-$-657.94M-$-1.74B
Depreciation and amortization$27.6M$48.5M$41.2M$29.1M$12.7M
Stock-based compensation$36M$48.2M$85.4M$130.3M$183.6M
Change in working capital-$-887.71M$48.5M-$-376.84M-$-361.15M$1.73B
Accounts receivable$61M$354.1M-$-274.44M$249.2M-$-192.26M
Inventory-$-3.24M$12.9M-$-74.46M-$-477.8M-$-600.33M
Accounts payable-$-322.57M-$-385.63M-$-378.81M$913.4M$600.3M
Net cash provided by operating activities-$-244.63M-$-87.26M-$-713.97M-$-415.94M$323M
Investments in property, plant and equipment-$-5.56M-$-14.64M-$-58.81M-$-92.98M-$-57.49M
Acquisitions, net$0.00$192.6M$0.00$0.00$57.5M
Net cash used for investing activities-$-78.27M-$-204.04M-$-58.81M-$-92.98M$100.2M
Common stock issued$0.00$263.3M$360.2M$249.2M$564.9M
Common stock repurchased-$-4.8M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.7M$260.6M$4.47M$325M$461.7M
Net change in cash-$-289.24M-$-38.52M-$-765.03M-$-179.41M$879.5M
Cash at end of period$256.1M$545.3M$583.8M$1.35B$1.53B
Operating cash flow-$-244.63M-$-87.26M-$-713.97M-$-415.94M$323M
Capital expenditure-$-5.56M-$-13.06M-$-58.81M-$-92.98M-$-57.49M
Free cash flow-$-250.19M-$-100.32M-$-772.77M-$-508.92M$265.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Novavax, Inc.

        Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

        CEO
        John Charles Jacobs
        Employees
        749
        Beta
        2.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Novavax, Inc. (NVAX)?

        Novavax, Inc. (NVAX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NVAX undervalued?

        NVAX trades at a price of $7.47 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.